Abstract
Immunostimulatory antibodies in cancer rely on different mechanisms of action, simple blocking of immune checkpoints, depletion of tumour-infiltrating regulatory T cells, agonistic action on lymphocyte activatory receptors, etc. Choosing the relevant heavy chain isotype or the adequate engineering variant of this heavy chain is critical for the therapeutic efficacy, since the aforementioned properties sometimes bring into play the Fc region and the hinge region. This short review tries to learn the lessons from the clinical experience.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
